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1. Introduction 
There are millions of patients suffering from fatal liver disease in the world. Whole-organ 
transplantation of the liver, such as orthotopic liver transplantation (OLT), improves the 
survival rate of these patients (Benten et al., 2009). However, the traditional OLT is still 
limited due to the serious want of viable livers available for organ transplantation. 
Therefore, cell therapies for the treatment of end-stage hepatic diseases are currently under 
investigation all over the world (Ito et al., 2009). The simplest method for cell therapies is by 
transplantation of primary hepatocytes isolated from the donor. Experimental studies on 
animals have shown that transplanted primary hepatocytes into the spleen or portal vein of 
host animals repopulated in the liver, suggesting that the primary hepatocyte 
transplantation may be successful as an alternative to organ transplantation for patients 
with liver failure (Sutherland et al., 1977; Makowka L et al., 1980; Demetrious et al., 1986; 
Arkadopoulos et al., 1998; Ribeiro et al., 1992; Ito et al., 2007; Nagata et al., 2003; Kobayashi 
et al., 2000). However, success in clinical use is limited (Fox et al., 1998; Platt, 1998) and 
donor human livers to isolate the hepatocytes for hepatocyte transplantations are also 
limited, since these organs are needed to use in organ transplantation. Furthermore, the 
primary hepatocytes are cultured in vitro with very limited success due to their slow growth 
and instability of hepatic phenotype tending to lose differentiation character (Clayton & 
Darnell, 1983). Thus, although the human primary hepatocytes are ideal cells for cell 
therapies, an unlimited source of hepatocytes is required. There are two ways to prepare an 
unlimited supply of hepatocytes: 1) induction of differentiation from pluripotent stem cells, 
such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) and 2) 
production of hepatocytes from somatic cells by reactivation of mature hepatocytes 
themselves or reprogramming the somatic cells other than hepatocytes into hepatocytes.  
ESC and iPSC are expected to be a promising alternative resources for cell therapy because 
they are pluripotent, making it possible to produce any type of tissue from a single resource 
and they are also an infinite resource expanding continuously in the undifferentiated state 
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under appropriate conditions (Hanna et al., 2010). A lot of studies have reported the 
successful induction of hepatic differentiation from ESCs and iPSCs (reviewed in Andersson 
& Lendahl, 2009; Behbahan et al., 2011; Greenbaum, 2010; Kung & Forbes, 2009). However, 
undifferentiated pluripotent stem cells possess intrinsic property of teratoma formation in 
the host after transplantation (Fong et al., 2010; Blum & Benvenisty, 2009; Knoepfler, 2009) 
and their induction efficiency of hepatocellular differentiation was still not enough so that 
various types of cells, including undifferentiated pluripotent stem cells, remained at 
different stages of differentiation (Sasaki et al., 2009; Shiraki et al., 2008; Teratani et al., 2005; 
Yoshie et al., 2010). Thus, improvement of the induction method for the hepatocellular 
differentiation to the efficiency of almost 100% and/or development of an efficient selection 
method for differentiated hepatocytes are needed.  
Several strategies for isolation of ES cell-derived hepatic cells have been proposed in the last 
decade (Basma et al., 2009; Duan et al., 2007; Gouon-Evans et al., 2006; Heo et al., 2006; Li et 
al., 2010; Soto-Gutierrez et al., 2006; Suzuki et al., 2000; Yin et al., 2002). The method of 
isolation is based on the sorting system, such as fluorescence-activated cell sorting (FACS) 
or magnetic-activated cell sorting (MACS) devices and utilizes fluorescent markers or 
antibodies specific for hepatic cells. To realize enough quality and quantity, we propose in 
this paper a dual selection method; first the proliferative immature hepatocytes are isolated 
with a cell surface marker Liv2 antigen and after growing fully in the culture, differentiated 
mature hepatocytes are purified with indocyanine green (ICG) which is an organic anion 
that is specifically taken by mature hepatocytes. We suggest that in surface markers only 
Liv2 antigen is used in the specific isolation of immature hepatocytes from pluripotent stem 
cells (Takashimizu et al., 2009). Purification with ICG has the two major benefits of being 
both safe and inexpensive, since the ICG system that we are developing is non-immune 
based and a non-genetically engineered method for selection of differentiated hepatocytes 
by using flow cytometry with a newly developed laser beam suitable for excitation of ICG.  
Except for cell therapy, human hepatocytes are also useful and necessary for drug 
development (Greenhough et al., 2010). The liver is the central site of drug metabolism and 
detoxication and thus liver based toxicological tests for developing drugs are necessary. 
However, preclinical studies of model animals are inadequate to fully evaluate toxicity due 
to species variation of hepatic functions, such as cytochrome P450 induction (Lake, 2009). 
This remark is also true for food development. Therefore, the strategy described here is 
applicable to a wide area of health science.  
2. How to obtain hepatocytes 
2.1 Hepatocyte induction by differentiating from pluripotent stem cells (ESCs or 
iPSCs) 
Induction of differentiation from pluripotent stem cells into hepatocytes was performed by 
mimicking the hepatocyte differentiation during embryonic development. During 
embryonic development, hepatocytes are differentiated from the definitive endoderm and 
the definitive endoderm is generated from the mesendoderm, which is induced under the 
influence of Nodal, a transforming growth factor beta (TGF-beta) family gene product 
(Zaret, 2000; Zaret & Grompe, 2008). The hepatocyte differentiation from the definitive 
endoderm or mesendoderm is induced by FGF signalling from the cardiac mesoderm and 
BMP-4 signalling from the septum transversum mesenchyme (Duncan, 2003; Si-Tayeb et al., 
2010; Zaret, 2001). Thus, the procedure for induction of hepatocyte differentiation from 
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pluripotent stem cells consists of two steps: the first is definitive endoderm induction by 
activin, which acts in a similar way to Nodal, the second is hepatocyte induction by FGF and 
BMP-4. However, because the cells induced with this procedure are not fully maturated, we 
further induce maturation with serum-free Lanford medium, which is developed for 
maintaining human hepatocytes in vitro (Sasaki et al., 2009; Yoshie et al., 2010). 
2.1.1 Induction of hepatocyte differentiation from mouse ESCs 
Although, in most studies, the differentiation-inducing experiments were performed under 
serum-containing conditions (e.g. Ishii et al., 2005), the hepatocytes induced using these 
conditions have inevitable risks, such as viral infection advising against use in possible 
future clinical applications. Therefore, we propose a simple two-step induction method 
under serum-free conditions as below (Yoshie et al., 2010). 
 
 
Fig. 1. Experimental design for the induction of hepatocytes from mouse ESCs. 
As a first step, the mesendoderm was induced by activin as shown in Fig. 1. The expression 
of the mesendodermal marker goosecoid and the primary endoderm marker Foxa2 were 
increased approximately twofold under serum-free conditions than under serum-containing 
conditions at 100 ng/ml of activin which mimics the role of Nodal signals (Kubo et al., 
2004), suggesting that unknown serum factors inhibited hepatic differentiation. 
Next, as a second step, hepatocytes were induced from the mesendoderm with serum-free 
Lanford medium, which has been developed for maintaining human hepatocytes (Lanford 
et al., 1989). Once immersed in the Lanford medium, the embryoid bodies (EBs) began to 
show typical hepatic features by day 17, including the expression of hepatic lineage markers 
albumin (ALB), alpha fetoprotein (AFP), transthyretin (TTR) and α1-anti-trypsin (AAT) 
detected by RT-PCR, and ALB, AFP and cytokeratin-18 (CK18) detected by immunostaining. 
On day 22, these cells seemed to have become mature, functional hepatocytes characterized 
by the expression of metabolizing enzymes, including DPPIV/UDP-glucuronosyl 
transferase (Ugt1a1), Slcola4, cyp3a11, cyp2b10 and cyp7a1 detected by real-time PCR, a 50-
fold greater cyp3A11 response than the control with 100uM dexamethasone stimulation. 
These results indicate that this simple two-step induction method under serum-free 
conditions induces high quality hepatic lineage cells directly from mouse embryonic stem 
(ES) cell-derived mesendoderm.  
2.1.2 Induction of hepatocyte differentiation from human ESCs or iPSCs 
From embryonic events we learn how to differentiate hepatocytes from pluripotent stem 
cells. Put simply, FGF produced from cardiac mesoderm triggers hepatic buds from the 
endoderm-originated tube, BMP-4 from septum transversum promotes differentiation and 
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proliferation, cytokine, such as OSM, leads them to the final stage (Duncan, 2003). Many 
methods to differentiate have been developed and practiced (Cai et al., 2007; Hu et al., 2003; 
Ishii et al., 2008; Pei et al., 2009; Soto-Gutierrez et al., 2006; Teratani et al., 2005). Curiously, 
however, they deleted BMP-4 produced from septum transversum, which is an 
indispensible factor for hepatic development. So we have developed a new protocol to 
differentiate EB prepared from H1,khES1,2,3 ES lines into hepatocytes (Sasaki et al., 2009): 
25 ng/ml acidic fibroblast growth factor (aFGF) and 25ng/ml basic fibroblast growth factor 
(bFGF for the first 3 days; 20 ng/ml BMP-4and 20 ng/ml hepatocyte growth factor (HGF) 
for the next 3 days, and 20 ng/ml oncostatin M (OSM) and 20 ng/ml vascular endothelial  
 
 
Fig. 2. Induction of hepatocyte differentiation from human ESCs . a. RT-PCR analysis of gene 
expressions associated with hepatic differentiation. Prox1 is definitely recognized in the OSM 
stage. Albumin is definite in the Lanford stage. G6P appears from the BMP-4 stage. b. The 
cluster of large cells with binucleate (arrows). c. Fine structures of the cytoplasm of 
differentiated hepatocytes. rER are layered (arrow). d. The junctional areas show bile canaliculi 
with microvilli (white arrow). Round mitochondria are rich in the cytoplasm (black arrow). 
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growth factor (VEGF) for the third set of 3 days; the modified Lanford medium for an 
additional 2 weeks. RT-PCR showed switch-on to hepatocyte maturation in the BMP-4 stage 
(Fig.2a), but it was quickly recognized that Lanford medium was a powerful promoter for  
cellular maturation. Therefore, Lanford medium was developed to maintain primary 
hepatocytes without serum. The contents contain growth factors and hormone, including EGF, 
LCGF, prolactin insulin and glucagon (Lanford et al., 1989). It remains unknown which factors 
are more effective, but it is true that some of them, or all, progress maturation powerfully 
(Sasaki et al., 2009; Yoshie et al., 2010). Drastic morphological changes had not been recognized 
during the periods from FGF stage to OMS, though gene expression showed signs of 
hepatocyte differentiation. However, several days later in the Lanford medium, the cells 
enlarged, took polyhedral forms and formed hepatocyte-like colonies with two-nuclei and 
large cytoplasm (Fig.2b). As described in our paper, they showed many gene expressions seen 
in mature hepatocytes, ICG uptake and albumin production. However, it was the TEM images 
that made us confirm that they were hepatocytes. They contained all the features with which 
morphologists determine that they are hepatocytes (Fig.2c, d). But this method, as well as 
other methods, has fatal defects. It is complicated, has no ability to produce a large number of 
hepatocytes at the final differentiation stage and requires high cost to use many growth 
factors. For clinical application, a simpler method has to be developed.  
2.2 Hepatocyte reactivation or transdifferentiation from somatic cells 
Although the liver is well known to have remarkable regenerative potential, the 
pathological liver has a limited ability to regenerate and the hepatocytes isolated from the 
living liver do not proliferate with ease in vitro (Clayton et al., 1983). However, by using 
gene transfer techniques similar to that used in the production of iPSC, reactivation of the 
hepatocytes or reprogramming of the somatic cells to hepatocytes is possible. It has been 
reported that rat primary hepatocytes, immortalized with oncogenic simian virus 40 T 
antigen (SV40Tag) could grow in vitro and maintain differentiated hepatic phenotype (Cai 
et al., 2000, 2002; Schumacher et al., 1996; Tada et al., 1998). Additionally, following 
transplantation into host rodents with liver failure, these immortalized hepatocytes function 
as well as primary hepatocytes and improve survival. However, although the SV40 T 
antigen can be excised by genetic engineering (e.g. Cre/lox recombination), the 
reprogramming to proliferative state by SV40Tag is thought not to be physiological as SV40 
T antigen is a virus gene. We found some endogenous genes which when expressed in the 
proliferative hepatic cells could stimulate the growth of rat primary hepatocytes, following 
gene transfer, in vitro (unpublished data), so we expect that hepatocytes can be reactivated 
physiologically by these methods. However, to prevent immune rejection in cell therapy, 
these hepatocyte reactivation strategies have to utilize primary hepatocytes from the patient 
with end-stage liver pathologies or transfer the gene(s) into the patient’s liver. Recently, it 
was reported that functional hepatocyte-like (iHep) cells could be induced directly from 
mouse tail-tip fibroblasts by gene transfer of Gata4, Hnf1a and Foxa3 (Huang et al., 2011). 
The transplanted iHep cells repopulated the livers of mice deficient in fumarylacetoacetate 
hydrolase (Fah) gene, restored liver functions and rescued almost half of recipients. 
Moreover, recently, we showed gene transfer unmediated transdifferentiation between 
hepatocytes and pancreatic cells (Kanoh et al., 2011). Thus, in addition to the induction from 
pluripotent stem cells, the strategy of direct induction from somatic cells will provide 
promising methods to prepare functional hepatocytes for regenerative medicine and 
toxicological tests. 
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3. Applicative aspects of the prepared hepatocytes 
3.1 Research for realization of the cell replacement therapy 
The major problems concerning realization of the hepatic cell therapy are: (i) existence of 
undifferentiated cells in the induced hepatocyte sample and (ii) difficulty in the 
establishment and functioning of transplanted hepatocytes. To solve the first problem, we 
are trying to establish two selection techniques: 1) isolation of immature hepatocytes with a 
cell surface marker Liv2 antigen and 2) purification of differentiated hepatocytes with 
indocyanine green (ICG). The immature hepatocytes isolated with Liv2 antigen retain 
proliferative capacity and therefore the collection of immature hepatocytes can be amplified 
in this step. Although the maturation to functional hepatocyte is usually difficult, the flow 
cytometry with laser beam for ICG could specifically purify functional hepatocytes, because 
uptake of ICG is hepatocyte-specific function and ICG is incorporated by only functional 
hepatocytes. The second problem could be partly solved by improving the transplant 
method. Because the liver with cirrhosis cannot accept transplanted cells, we are examining 
the transplant method that plants hepatocytes into the submucosa of the duodenum as 
mentioned in the last section of this chapter. In this way, the bile produced by the 
hepatocyte may be flowed into the lumen of the duodenum appropriately. 
3.1.2 Isolation of immature hepatocytes with Liv2 antibody  
Although various cytoplasmic markers, such as ALB, AFP and glucose-6-phosphatase (G6P), 
have been reported as useful for identifying immature and mature hepatocytes, these are not 
surface markers, so it is impossible to isolate only living hepatocytes using the fluorescence-
activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) method. An isolating 
method using several surface antigens of hematopoietic markers to select hepatocytes has been 
reported (Suzuki et al., 2000), but the method is insufficient due to inaccurate cell counts and 
contamination of other types of cells in addition to hematopoietic cells and hepatocytes. Liv2, 
which was first reported by Watanabe et al. (Watanabe et al., 2002) is selectively detected in 
the cell surface of fetal mouse liver cells of embryonic day E9.5 to E12, so it can be used as a 
surface marker to isolate immature hepatocytes. 
We have performed immunocytochemical analysis to verify the presence of Liv2 in 
immature hepatocytes derived from ES cells (Takashimizu et al., 2009) and we found 
clusters of Liv2-positive cells in EB outgrowth with the same patterns as the 
immunoreactivity seen in the E9.5 immature hepatocytes. In addition, we analyzed 
microlocalization of the Liv2 antigen by immuno-TEM (ImmunoGold) and confirmed 
definitely that Liv2 is a surface antigen. Next, we analyzed the property of Liv2-positive 
cells isolated by MACS. Cell counting and MTT assay revealed that Liv2-positive cells 
isolated by MACS from the primary hepatocytes obtained from the fetal livers of E12 mouse 
embryos have moderate proliferative potential (Figure 3).  
Double-Immunostaining of the isolated cells of 1 day after Liv2-MACS showed that all of 
Liv2-positive cells analyzed express Prox1, AFP and ALB (Figure 4). Both Prox1 and AFP 
are markers of immature hepatocytes and not express in the adult liver cells. Thus, it was 
demonstrated that in the cells obtained from E12 fetal livers, only immature hepatocytes 
were positive for Liv2. 
Further cultivation of the isolated cells confirmed that these Liv2-positive cells were 
progenitors of mature hepatocytes and could differentiate into mature hepatic cells. 
Immunocytochemical analysis showed that although population of Liv2-positive cells was 
decreased 5 days after culture, positive cells for AFP and ALB increased (Figure 4).  
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Fig. 3. Proliferation of Liv2-positive cells isolated by MACS. a: cell counting. b: MTT assay.  
 
 
Fig. 4. Immunocytochemical analysis of cultured cells isolated by MACS with Liv2 antibody. 
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RT-PCR analysis revealed that the expression of mature hepatocyte markers CYP7A1, G6P, 
TAT and TTR was initially very low or absent and increased gradually afterward (Figure 
5A). Moreover, the expression of CK7, a maker of bile duct cells, was extremely low on the 
first day and drastically up-regulated on day 5 (Figure 5b), suggesting that the Liv2-positive 
cells were bipotential progenitors capable of producing both hepatocytes and bile duct cells.  
 
 
Fig. 5. Analysis of gene expression of mature hepatocyte makers in Liv2 positive cells 
cultured with Lanford medium. a; RT-PCR，b; Real-Time RT-PCR. 
Taken together, these data strongly suggest that Liv2-positive cells are immature 
hepatocytes normally contributing to embryonic development and that anti-Liv2 antibody 
can be used to isolate immature hepatocytes derived from ESCs. 
There is only one report adopting a similar strategy by purifying hepatic progenitor cells 
rather than mature hepatic cells with surface antigens (Li et al., 2010). They successfully 
isolated hepatic progenitors by FACS with c-Kit and EpCAM antibody, and demonstrated 
that these c-Kit-negative, EpCAM-positive cells could undergo long-term expansion with 
sustained hepatoblast-like characteristics. Moreover, they cloned the hepatoblast-like cells 
and showed these clones repopulated in the host livers without inducing tumorigenesis. 
Although EpCAM expressed in hepatic progenitor cells rather than adult hepatocytes, 
EpCAM also expressed in many other cells such as undifferentiated ESCs and definitive 
endoderm cells. Therefore, they complemented EpCAM in positive selection with c-Kit in 
negative selection since c-Kit is only expressed on ESCs, definitive endoderm cells and some 
mesoderm cells, but not hepatic cells. However, there may be other cells with c-Kit-negative 
and EpCAM-positive other than hepatic progenitor and the success of their strategy is 
thought to depend on their efficient induction of definitive endoderm from mouse ESCs. On 
the other hand, to isolate immature hepatocytes, we use single antibody (Liv2) highly 
specific to immature hepatocytes. Although anti-Liv2 antibody specifically recognizes 
rodent Liv2 antigen, but not human and gene encoding, its Liv2 antigen is still unclear, 
however, a human counterpart must exist considering the evolutionary relationship 
between rodent and human. Developing tools for biochemical analysis, such as mass 
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spectrometry, are expected to reveal the Liv2 gene. Thus, we expect the development of an 
isolating system for human immature hepatocytes with anti-Liv2 antibody recognizing 
human Liv2 in the future.  
3.1.3 Isolation of mature hepatocytes with ICG 
There are a lot of protocols for generating hepatocytes from ESCs or iPSCs in vitro, but 
purifying mature hepatocytes is still difficult and many different cell types remain. Several 
studies have used ESC lines transfected with the green fluorescent protein reporter gene 
controlled by promoters of hepatic genes, such as Foxa2 (Gouon-Evans et al., 2006), Afp (Yin 
et al., 2002), ALB (Heo et al., 2006; Soto-Gutierrez et al., 2006) and a1-antitrypsin (Aat) (Duan 
et al., 2007). However, these strategies need genetic manipulation that is not suited to the 
future therapeutic applications and GFP is known to have slight toxicity to cells. Moreover, 
mature hepatocytes rather than immature hepatocytes are known to be unstable in vitro. 
Thus, a particularly safe method is required for selecting mature hepatocytes derived from 
ESCs or iPSCs. 
Indocyanine green (ICG) is a nontoxic organic anion that is eliminated exclusively by 
hepatocytes and is clinically used as a test substance to evaluate liver function (Berk & 
Stremmel, 1986). The uptake and release of ICG are frequently used to identify and/or 
evaluate ESC-derived hepatocytes (Agarwal et al., 2008; Farzaneh et al., 2010; Yamada et al., 
2002). The fluorescence of ICG can be observed at 800-900 nm with appropriate excitation of 
near 780 nm. Therefore, we developed a flow cytometer equipped with an excitation laser of 
785 nm to detect ICG-positive cells (Yoshie et al., manuscript in preparation). We 
determined optimal concentration and incubation time for detection of ICG uptake and 
showed that rat primary hepatocytes and ESC-derived hepatocytes selectively took up ICG. 
Although irradiation of ICG with a laser at 100 J/cm2 was reported to generate singlet 
oxygen (1O2), which is damaging to cells (Hirano et al., 2007), the power of our laser 
(FISHMAN-R) was 5 mJ/cm2 and much less likely to generate singlet oxygen. In fact, in 
analysis with trypan blue exclusion, the analyzed cells were not damaged by FISHMAN-R 
laser flow cytometry. 
Similar sorting methods of hepatocytes or hepatocyte-like cells by use of antibodies are 
frequently reported, e.g. isolation of mature hepatocyte-like cells by FACS with 
sialoglycoprotein-receptor (Basma et al., 2009). However, because the purification of mature 
hepatocytes is thought to be a final step and the mature hepatocytes have limited 
proliferative potential, this purification step must be massive i.e. sorting a lot of hepatocytes. 
Therefore, use of antibodies in this step is inadequate in the cost performance, as the 
antibodies are expensive. Our detection system which relies on the selective uptake by 
hepatocytes of ICG, a stable and inexpensive fluorescent chemical compound, overcomes 
this problem and will lead to the development of an effective system for purifying 
hepatocytes derived from ESCs, iPSCs or somatic cells.  
3.2 Use of hepatocytes for toxicology and drug development 
The liver is centre of metabolism and the hepatocytes are responsible for metabolizing most 
compounds in vivo. Therefore, the cultured hepatocyte can be used to predict how drugs 
are metabolized and to what extent they may be toxic. These tests include use of primary 
rodent hepatocytes and human immortalised hepatocyte cell lines, such as HepG2 (Rudzok 
et al., 2010). However, the rodent hepatocytes have species-specific differences in 
metabolizing function from human (Lake, 2009) and immortalised hepatocytes have poor 
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hepatic function and sometimes have an abnormal karyotype (Wong et al., 2000). Thus, 
human primary hepatocytes have become a standard tool for evaluating hepatic drug 
metabolism in vitro. However, to do so demands a lot of functional hepatocytes and the 
utility of the human primary hepatocyte is seriously limited. Our induction and selection 
methods will be helpful to meet the demand of these examination systems as an alternative 
to primary human hepatocytes. Particularly, dual selection strategies mentioned above are 
suited for scalable production of human hepatocytes. Immature hepatocytes isolated with 
Liv2 were suggested to have unlimited proliferative potential (Figure 3) and could serve the 
scalable production. Although expanded immature hepatocytes have to differentiate into 
mature hepatocytes, our protocol could efficiently induce maturation with Lanford medium 
and the functional, mature hepatocytes that must be in large amounts could be purified 
inexpensively by FACS with ICG. 
4. Further problems 
4.1 In vitro tissue formation using induced hepatocytes 
Besides immature hepatocytes being acceptable in some cases of hepatocyte transplantation 
due to hepatic maturation after transplantation, immature hepatocytes are absolutely 
unacceptable for use in evaluating hepatic drug metabolism in vitro. The mature functional 
hepatocytes are required in drug tests. However, in vitro induction of hepatic maturation or 
terminal differentiation has not been achieved enough. Realization of fully functional 
hepatocytes may require tissue organization similar to that of the liver in the living body. 
There is a dilemma in this problem: although the purification of hepatocytes is necessary for 
the improvement of the quality of induced hepatocytes, fully functional liver tissue requires 
various types of cells other than hepatic parenchymal cells. To solve this problem, we have 
three options: (i) selecting several types of cells and organizing them into tissue structure, 
(ii) selecting the precursor cells for histogenesis of liver, inducing differentiation and 
prompting self-organization and (iii) constructing artificial culture microenvironments 
mimicking native environments of liver. The culture microenvironments, such as microwell 
architecture (Mori et al., 2008), are well known to improve the function of cells, including 
hepatocytes (Sharma et al., 2010).  
Previously, we showed the induction of retinal cells by co-culturing with ESC-derived RPE 
cells (Yue et al., 2010). Now, we try to apply a combination of these co-culture and 
microwell methods to induce mature function of hepatocytes.  
4.2 Hepatocytes transplantation: Where or how are hepatocytes transplanted? 
Purified pluripotent stem cell-derived hepatocytes are transplanted into patients with fatal 
hepatic disease, in whom hepatic tissue structures are newly developed and function. Thus, 
a new therapy for incurable hepatic disease substituting liver transplantation is established, 
which is a final goal of regenerative medicine.  
The problems to overcome for successful regenerative medicine are to determine the 
appropriate sites for effective cellular survival and function, and the effective way, i.e. 
which should be selected for transplantation, cell type or tissue type. The best way still 
remains unknown. Most experimental studies show injection of pluripotent stem cell-
derived hepatocytes through the vein or directly into the liver as cell type. Mouse ESC-
derived hepatocytes were injected into the liver through the portal vein (Yamada et al., 
2002). HGF-treated bone marrow mesenchymal cells were transplanted through the caudal 
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vein into the liver of CCl4-injured rats and this was effective against liver damage (Oyagi et 
al., 2006). After multipotent progenitor cells derived from human umbilical cord blood were 
transplanted into the left lateral lobe of the liver of the CCl4-injured rats or through the 
portal vein, they differentiated into the hepatocyte-like cells and were useful in treating the 
injury (Moon et al., 2009). 
But there is extreme pessimism about these ideas, methods and practices because fatally 
damaged livers provide poor and severe environments, such as extreme fibrosis in cirrhosis, 
rapid cellular necrosis in liver failure etc. for transplanted fresh hepatocytes. It is more 
reasonable to transplant hepatocytes into good conditions with a rich blood supply 
ectopically. In fact, the first transplanted site performed in a human patient with cirrhosis 
was the spleen (Mito et al., 1992). According to their report, a part of the cirrhotic liver was 
resected, from which intact hepatocytes were isolated and were injected into the spleen; 
afterwards, the survival was confirmed. Their experimental reports using rats indicated that 
6 months later splenic tissues were substituted by the hepatic tissues consisting of hepatic 
cords and hepatic sinus (Kusano & Mito, 1982; Mito et al., 1979). Except the spleen, fat 
tissues are good sites for breeding hepatocytes and their survival has been shown in fat pads 
(Jirtle & Chalopoulos, 1965). One of the authors transplanted rat primary hepatocytes into 
the rat mesenteric fat tissues and confirmed their survival and tissue structure (Sasaki et al., 
1983) (Figure 6a). But ectopic transplantation has a significant problem: it has no way and 
route to discharge bile juice. Any definite answers have not been given yet, but we have 
some hints that might help to resolve the problem. For example, glands e.g. duodenal 
glands or pancreatic tissues are found in the submucosa of the intestine (Fig.6b, c). Clinically 
ectopic tissues e.g. pancreatic or stomach tissues are recognized. In evolution, primitive 
hepatic tissues are incorporated into the midintestine in the earth worm as chloragocytes with 
varied functions, including a storing function of endogenous substances, such as glycogen and 
lipids, and metals (Ireland & Richards, 1977) and intensive DAB reactivity (Fischer & Horvath,  
 
 
Fig. 6. Strategy of ectopic transplantation. a. The survival hepatocyte cluster in the rat intra-
mesenterium (arrow). b. The duodenal gland in the submucosa of the rat duodenum 
(arrow). c. The pancreatic tissue in the submucosa of the small intestine (arrow). 
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1978). The next function in shipworms is midgut glands consisting of large cells with 
binucleate (Strunk, 1959) and enhanced hepatic function in crabs and lobsters as 
hepatopancreas (James, 1989). In mammalian embryonic development, it is well-known that 
hepatic buds grow from the duodenum described above. Therefore, our idea is to transplant 
hepatocytes into the submucosa and return them into the mother site, the intestine.  
Our first trial was to confirm whether human ES cell-derived embryo bodies, which were 
treated with the previous cocktail (Takashimizu et al., 2009) and containing ICG-positive 
cells (Fig.7a), survived in the submucosa or in the intestine. Injection was insecure in that it 
was difficult to confirm where it was injected or whether hepatocytes or EBs remained there. 
Then, we have established a new technique for transplantation. The peritoneum and muscle 
layer of the nude rat was cut by an electronic scalpel and separated (Fig.7b), in whose shallow 
furrow EBs were arranged in order (Fig.7c). After the wound was closed (Fig.7d), one or two 
weeks later, the transplanted site was prepared for histological investigation. In the 
submucosa, unique tissues including duct like structures were found (fig.7e). The vascular  
 
 
Fig. 7. Transplantation of human ESC-derived hepatocyte-like cells into a rat duodenum. a. 
Human EB containing ICG positive cells (green). b. The linear cut line performed on the 
surface of the nude rat duodenum (arrow). c. EBs (arrow) are arranged in the shallow 
furrow. d. The wound was closed with 7-0 nylon. e. Histology of the treated duodenum. EB 
survives in the submucosa along with duct formation (arrows). f. Vascular supply is 
confirmed (arrow), but is not sinusoid-like. 
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supply did not penetrate the cell cluster, but rounded the periphery (Fig.7f). Hepatic sinus 
did not appear to be differentiated yet. We recognized transplanted cell clusters survived in 
this method, but did not confirm that they differentiated into functional hepatocytes from 
EBs containing ICG-positive cells. At that time, we did not have the method to purify 
pluripotent stem cell-derived hepatocytes from mixed varied cell types yet. As the ICG-
selection method has been established, as described above, purified hepatocytes will be 
transplanted and be confirmed to function and discharge bile juice into the intestine. 
Further, for clinical trials, we provide a new technique, fibre scope transplantation. To cut 
the muscular layer is to subject patients to opening the abdomen, whereas if hepatocytes 
were injected into the submucosa, patients’ discomfort would significantly decrease. But it 
remains unknown how hepatocytes are injected into the submucosa with the fibre scope, as 
fibre scope has not yet been developed for rats. The scope with the smallest diameter for use 
on a dog was tried through the stomach to attain the duodenum (Fig.8a). It was very 
difficult to inject into the mucosa on the same side, but was successful in swelling the 
mucosa on the opposite side (Fig.8b). Fibre scope transplantation will be an effective tool for 
endoderm-derived differentiated cells in addition to hepatocytes. 
 
 
Fig. 8. Fibre scope transplantation. a. The interior of the nude rat duodenum. The red 
mucosa and the needle for injection of the fibre scope (arrow) are recognized. White circle is 
the mark for the needle to insert. b. The needle is inserted into the mucosa. The mucosa 
swells after fluid injection (arrow). 
On the other hand, another problem is whether cell transplantation or tissue transplantation 
is better, more effective or reasonable. It will take a long time to determine this, or each 
method may be used according to varied conditions, such as kinds of disease, its progress 
and permitted transplanted site. But in conclusion we prefer tissue transplantation, because 
effective function is due to cell-to-cell interaction and tissue organization. Kikuchi et al. have 
developed a unique in site cell micropatterning system (Kikuchi et al., 2009). A 
photoresponsive cell culture surface was geometrically processed in situ with the UV 
irradiation to increase the cell adhesiveness of HepG2. After confirmation of HepG2 
adhesion to the first dot pattern, fibroblast, which adhered easily to the plate without the 
UV irradiation were introduced to fill gaps among the HepG2 dot pattern. This simple 
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geometric pattern caused a 50-fold increase of CYP3A than conventionally cultured HepG2. 
Cell transplantation breaks once-established cell-to-cell interaction and requires 
reorganization in vivo, which creates double the work.  
But three methods to complete tissue transplantation have to be established, the in vitro 
method of tissue organization, which geometric patterning described above helps, the 
technique to transport in vitro established tissue into in vivo without destruction and the 
method to acquire rapid blood supply after transplantation. 
Scaffold-engineering may be essential to tissue transplantation, because it is easily 
transported in intact conditions and is processed for drug delivery systems e.g. slow 
releasing angiogenic factors (Hou et al., 2011). Collagen or modified collagen sponges were 
conventionally used as cell carriers in many labs, as well as in ours (Imamura et al., 2004; 
Kanematsu et al., 2004; Takimoto et al., 2003). The above collagen-based scaffold is not 
complete, because cells did not expand rapidly within the sponge in vitro. After 
transplantation, the carrier was bounded on the periphery by the non-penetrating host 
tissue. Moreover, function, such as urea synthetic rate, decreased below the control level 
(Hasirci et al., 2001). In addition to collagen-based materials, many other materials and 
methods are proposed (Kano et al., 2008; Katsuda et al., 2010; Torok et al., 2011), which will 
steadily improve tissue transplantation techniques. In the future it is expected that simpler, 
easier, more effective and more practical transplantation techniques will be developed. 
5. Conclusion 
In this chapter, we described the production and selection of hepatocytes and show a 
strategy for regenerative medicine using pluripotent-derived hepatocytes. There are two 
sources to obtain hepatocytes: (i) somatic cells, such as mature hepatocytes themselves and 
(ii) multi- or pluripotent stem cells, such as embryonic stem cells (ESCs) and induced 
pluripotent stem cells (iPSCs). We have reported the methods for induction of 
differentiation from pluripotent stem cells. Our protocols for induction of differentiation 
from pluripotent stem cells mimic the hepatocellular differentiation during embryonic 
development.  
One important problem of the differentiation-mediated preparation of hepatocytes is how to 
exclude undifferentiated cells, while a lot of hepatocytes are produced. Additionally, it is 
impossible to improve the efficiency of hepatocellular differentiation to 100% and the 
remaining undifferentiated cells have the potential to cause teratoma after being 
transplanted into the host. To isolate hepatocytes, we proposed a dual selection method. The 
first is isolation of immature hepatocytes by cell sorting with Liv2, which specifically detects 
immature hepatocytes. The second is purification of mature hepatocytes by low cost sorting 
with ICG, following massive expansion of immature hepatocytes and induction of 
differentiation into mature hepatocytes with Lanford medium. The flow of our method is as 
below: 
i. Induction of immature hepatocytes from pluripotent stem cells  
ii. Isolation of proliferative immature hepatocytes with anti-Liv2 antibody 
iii. Large scale culture expanding the immature hepatocytes and induction of 
differentiation into mature hepatocytes 
iv. Low cost and safe purification of functional mature hepatocytes by FACS with ICG 
The next step is in vitro and in vivo tissue formation. The culture condition mimicking 
tissue organization improves the function of cells, including hepatocytes. Moreover, to 
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realize the therapy for patients with incurable hepatic disease, it is necessary to promote 
tissue organization artificially in vivo. We propose that for the artificial organization of 
hepatic tissue, heterotropic transplantation into submucosa of the duodenum is most 
suitable, since the liver with incurable disease does not accept the transplanted hepatocytes 
easily.  
6. Acknowledgments 
We gratefully thank Ms. Kayo Suzuki and Dr. Kiyokazu Kametani (Research Center for 
Instrumental Analysis, Shinshu University) for their excellent technical assistance. 
7. References 
Andersson, ER. & Lendahl, U. J (2009). Regenerative medicine: a 2009 overview. Intern Med. 
266(4):303-310 
Agarwal, S.; Holton, K.L. & Lanza, R. (2008). Efficient differentiation of functional 
hepatocytes from human embryonic stem cells. Stem Cells 26: 1117-1127 
Arkadopoulos, N.; Chen, SC.; Khalili, T.M.; Detry O.; Hewitt, WR.; Lilja, H.; Kamachi, H.; 
Petrovic, L.; Mullon, CJ.; Demetriou, AA. & Rozga, J. (1998). Transplantation of 
hepatocytes for prevention of intracranial hypertension in pigs with ischemic liver 
failure. Cell Transplant.7:357-363 
Basma, H.; Soto-Gutierrez, A.; Yannam, GR.; Liu, L.; Ito, R.; Yamamoto, T.; Ellis, E.; Carson, 
SD.; Sato, S.; Chen, Y.; Muirhead, D.; Navarro-Alvarez, N.; Wong, RJ.; Roy-
Chowdhury, J.; Platt, JL.; Mercer, DF.; Miller, JD.; Strom, SC.; Kobayashi, N.; Fox, 
IJ. (2009). Differentiation and transplantation of human embryonic stem cell-
derived hepatocytes. Gastroenterology 136:990-999  
Behbahan, IS.; Duan, Y.; Lam, A.; Khoobyari, S.; Ma, X.; Ahuja, TP. & Zern, MA. (2011). New 
approaches in the differentiation of human embryonic stem cells and induced 
pluripotent stem cells toward hepatocytes. Stem Cell Rev. Feb 19. [Epub ahead of 
print]  
Berk, PD. & Stremmel, W. (1986). Hepatocellular uptake of organic anions. Prog. Liver Dis. 
8:125-144 
Benten, D.; Staufer, K. & Sterneck, M. (2009). Orthotopic liver transplantation and what to 
do during follow-up: recommendations for the practitioner. Nat. Clin. Pract. 
Gastroenterol Hepatol. 2009 6(1):23-36 
Blum, B.& Benvenisty, N. (2009). The tumorigenicity of diploid and aneuploid human 
pluripotent stem cells. Cell Cycle 8(23):3822-3830 
Cai, J.; Ito, M.; Westerman, K.; Kobayashi, N.; Leboulch, P. & Fox, IJ. (2000). Construction of 
a non-tumorigenic rat hepatocyte cell line for transplantation: reversal of 
hepatocyte immortalization by site-specific excision of the SV40 T antigen. J. 
Hepatol. 33:701-708 
Cai, J.; Ito, M.; Nagata, H.; Westerman, KA.; Lafleur, D.; Chowdhury, JR.; Leboulch, P. & 
Fox, IJ. (2002). Treatment of liver failure in rats with end-stage cirrhosis by 
transplantation of immortalized hepatocytes. Hepatology. 36(2):386-394 
Cai, J.; Zhao, Y.; Liu, Y.; Ye, F.; Song, Z.; Qin, H.; Meng, S.; Chen, Y.; Zhou, R.; Song, X.; Guo, 
Y.; Ding, M. & Deng, H. (2007). Directed differentiation of human embryonic stem 
cells into functional hepatic cells. Hepatology 45,1229-1239 
www.intechopen.com
 Advances in Regenerative Medicine 160 
Clayton, DF. & Darnell, JE. Jr. (1983). Changes in liver specific compared to common gene 
transcription during primary culture of mouse hepatocytes. Molecular and Cellular 
Biology 3 (9).; 1552-1561 
Demetrious, AA.; Levenson, SM.; Novikoff, PM.; Novikovv, AB.; Chowdhury, NR.; Whiting, 
J.; Reisner, A. & Chowdhury, JR. (1986). Survival, organization and function of 
microcarrier-attached hepatocytes transplanted in rats. Proc. Natl. Acad. Sci. USA 
83:7475-7479 
Duncan, SA.; (2003). Mechanisms controlling early development of the liver. Mech.Dev.120 
19-33 
Duan, Y.; Catana, A.; Meng, Y.; Yamamoto, N.; He, S.; Gupta, S.; Gambhir, SS.; Zern, MA. 
(2007). Differentiation and enrichment of hepatocyte-like cells from human 
embryonic stem cells in vitro and in vivo. Stem Cells 25:3058-3068 
Farzaneh, Z.; Pournasr, B.; Ebrahimi, M.; Aghdami, N. & Baharvand, H. (2010). Enhanced 
functions of human embryonic stem cell-derived hepatocyte-like cells on three-
dimensional nanofibrillar surfaces. Stem Cells Rev. 6: 601-610 
Fischer, E. & Horvath, I. (1978). Evidence of the presence of extraperoxisomal catalase in 
chloragogen cells of the earthworm, Lumbricus terrestris L. Histochemistry 
56(2):165-171 
Fong, CY.; Gauthaman, K. & Bongso, A. (2010). Teratomas from pluripotent stem cells: a 
clinical hurdle. J. Cell Biochem. 111(4):769-781 
Fox, IJ.; Chowdhury, JR.; Kaufman, SS.; Goertzen, TC.; Chowdhury, NR.; Warkentin, PI.; 
Dorko, K.; Sauter, BV. & Strom, SC. (1998). Treatment of Crigler-Najjar syndrome 
type I with hepatocyte transplantation. N. Engl. J. Med. 338:1422-1426 
Greenbaum LE. (2010). From skin cells to hepatocytes: advances in application of iPS cell 
technology. J. Clin. Invest. 120(9):3102-3105 
Gouon-Evans, V.; Boussemart, L.; Gadue, P.; Nierhoff, D.; Koehler, CI.; Kubo, A.; Shafritz, 
DA.; Keller, G. (2006). BMP-4 is required for hepatic specification of mouse 
embryonic stem cell-derived definitive endoderm. Nat Biotechnol 24:1402-1411 
Greenhough, S.; Medine, CN. & Hay DC. (2010). Pluripotent stem cell-derived hepatocyte-
like cells and their potential in toxicity screening. Toxicology 278(3):250-255 
Hanna, JH.; Saha K. & Jaenisch R. (2010) Pluripotency and cellular reprogramming: facts, 
hypotheses, unresolved issues. Cell. 143(4):508-525 
Hasirci, V.; Berthiaume, F.; Bondre, SP.; Gresser, JD.; Trantolo, DJ.; Toner, M. & Wise DL. 
(2001). Expression of liver-specific functions by rat hepatocytes seeded in treated 
poly (lactic-co-glycolic) acid biodegradable foams. Tissue Eng. 7(4):385-394 
Heo, J.; Factor, VM.; Uren, T.; Takahama, Y.; Lee, JS.; Major, M.; Feinstone, SM.; 
Thorgeirsson, SS. (2006). Hepatic precursors derived from murine embryonic stem 
cells contribute to regeneration of injured liver. Hepatology 44:1478-1486 
Hirano, T.; Kohno, E.; Gohto, Y. & Obana, A. (2007). Singlet oxygen generation by 
irradiation of Indocyanina Green (ICG) and its effect to tissues. Nippon Laser 
Igakkaishi 28: 122-128 
Hou, YT.; Ijima, H.; Takei, T.& Kawakami, K. (2011).Growth factor/heparin-immobilized 
collagen gel system enhances viability of transplanted hepatocytes and induces 
angiogenesis. J. Biosci. Bioeng. Jun 1. [Epub ahead of print] 
Hu, A.; Cai, J.; Zheng, Q.; He, X.; Pan, Y. & Li, L. (2003) Hepatic differentiation from 
embryonic stem cells in vitro. Chin. Med. J. 116, 1893-1897 
www.intechopen.com
 A Strategy Using Pluripotent Stem Cell-Derived Hepatocytes for Stem Cell-Based Therapies  161 
Huang, P.; He, Z.; Ji, S.; Sun, H.; Xiang, D.; Liu, C.; Hu, Y.; Wang, X. & Hui, L. (2011). 
Induction of functional hepatocyte-like cells from mouse fibroblasts by defined 
factors. Nature May 11. [Epub ahead of print]  
Imamura, T.; Cui, L.; Teng, R.; Johkura, K.; Okouchi, Y.; Asanuma, K.; Ogiwara, N. & Sasaki, 
K. (2004). Embryonic stem cell-derived embryoid bodies in three-dimensional 
culture system form hepatocyte-like cells in vitro and in vivo. Tissue Eng. 10(11-
12):1716-1724 
Ireland, MP. & Richards, KS. (1977). The occurrence and localisation of heavy metals and 
glycogen in the earthworms Lumbricus rubellus and Dendrobaena rubida from a 
heavy metal site. Histochemistry 51(2-3):153-166 
Ishii, T.; Yasuchika, K.; Fujii, H.; Hoppo, T.; Baba, S.; Naito, M.; Machimoto, T.; Kamo, N.; 
Suemori, H.; Nakatsuji, N. & Ikai I. (2005). In vitro differentiation and maturation 
of mouse embryonic stem cells into hepatocytes. Exp. Cell Res. 309(1):68-77 
Ishii, T.; Fukumitsu, K.; Yasuchika, K.; Adachi, K.; Kawase, E.; Suemori, H.; Nakatsuji, N.; 
Ikai, I. & Uemoto, S.(2008). Effects of extracellular matrixes and growth factors on 
the hepatic differentiation of human embryonic stem cells. Am. J. Physiol. 
Gastrointest. Liver Physiol. 295, G313-321 
Ito, M.; Nagata, H.; Yamamoto, T.; Yoshihara, D.; Fox, IJ. & Miyakawa, S. (2007). Intrasplenic 
hepatocyte transplantation prolonged the survival in Nagase analbuminemic rats 
with liver failure induced by common bile duct ligation. Cell Transplant. 16(5):547-
553 
Ito, M.; Nagata, H.; Miyakawa, S. & Fox IJ. (2009). Review of hepatocyte transplantation. J. 
Hepatobiliary Pancreat Surg. 16(2):97-100 
James MO. (1989). Cytochrome P450 monooxygenases in crustaceans. Xenobiotica 
19(10):1063-1076 
Jirtle, RJ. & Chalopoulos, GM. (1964). Effects of partial hepatectomy on transplanted 
hepatocytes. Cancer Res 24:1611-1625 
Kanematsu, A.; Yamamoto, S.; Ozeki, M.; Noguchi, T.; Kanatani, I.; Ogawa, O. & Tabata, Y. 
(2004). Collagenous matrices as release carriers of exogenous growth factors. 
Biomaterials 25(18):4513-4520 
Kano, K.; Yamato, M. & Okano, T. (2008). Ectopic transplantation of hepatocyte sheets 
fabricated with temperature-responsive culture dishes. Hepatol Res. 38(11):1140-
1147 
Kanoh, Y.; Tomotsune, D.; Shirasawa, S.; Yoshie, S.; Ichikawa, H.; Yokoyama, T.; Mae, S.; Ito, 
J.; Mizuguchi, M.; Matsumoto, K.; Yue, F. & Sasaki, K. (2011). In vitro 
transdifferentiation of HepG2 cells to pancreatic-like cells by CCl4, D-
Galactosamine, and ZnCl2. Pancreas [Epub ahead of print] 
Katsuda, T.; Teratani, T.; Ochiya, T. & Sakai Y. (2010). Transplantation of a fetal liver cell-
loaded hyaluronic acid sponge onto the mesentery recovers a Wilson's disease 
model rat. J. Biochem 148(3):281-288 
Kikuchi, K.; Sumaru, K.; Edahiro, J.; Ooshima, Y.; Sugiura, S.; Takagi, T. & Kanamori, T. 
(2009). Stepwise assembly of micropatterned co-cultures using photoresponsive 
culture surfaces and its application to hepatic tissue arrays. Biotechnol Bioeng. 
103(3):552-561 
Kusano, M. & Mito M. (1982). Observations on the fine structure of long-survived isolated 
hepatocytes inoculated into rat spleen. Gastroenterology. 82(4):616-628 
www.intechopen.com
 Advances in Regenerative Medicine 162 
Knoepfler, PS. (2009). Deconstructing stem cell tumorigenicity: a roadmap to safe 
regenerative medicine. Stem Cells 27(5):1050-1056 
Kobayashi, N.; Ito, M.; Nakamura, J.; Cai J.; Hammel, JM.& Fox, IJ. (2000). Treatment of 
carbon tetrachloride and phenobarbital-induced chronic liver failure with 
intrasplenic hepatocyte transplantation. Cell Transplant 9(5):671-673 
Kubo, A.; Shinozaki, K.; Shannon, JM.; Kouskoff, V.; Kennedy, M.; Woo, S,; Fehling, HJ. & 
Keller, G. (2004). Development of definitive endoderm from embryonic stem cells 
in culture. Development 131(7): 1651-1662 
Kung, JW. & Forbes, SJ. (2009). Stem cells and liver repair. Curr Opin Biotechnol. 20(5):568-74.  
Lake, BG.; (2009). Species’ differences in the hepatic effects of inducers of CYP2B and 
CYP4A subfamily forms: relationship to rodent liver tumour formation. Xenobiotica 
39:582-596 
Lanford, RE.; Carey, KD.; Estlack, LE.; Smith, GC. & Hay, RV. (1989). Analysis of plasma 
protein and lipoprotein synthesis in long-term primary cultures of baboon 
hepatocytes maintained in serum-free medium. In Vitro Cell Dev Biol. 25(2):174-182 
Li, F.; Liu, P.; Liu, C.; Xiang, D.; Deng, L.; Li, W.; Wangensteen, K.; Song, J.; Ma, Y.; Hui, L.; 
Wei, L.; Li, L.; Ding, X.; Hu, Y.; He, Z.; Wang, X. (2010). Hepatoblast-like progenitor 
cells derived from embryonic stem cells can repopulate livers of mice. 
Gastroenterology 139(6):2158-2169 
Makowka, L.; Rotstein. LE.; Falk, RE.; Falk, J. A.; Langer, B.; Nossal, NA.; Blendis, LM. & 
Phillips, MJ. (1980). Reversal of toxic and anoxic induced hepatic failure by 
syngeneic, allogeneic and xenogeneic hepatocyte transplantation. Surgery 88:244-
253 
Mito, M.; Kusano, M. & Kawaura, Y. (1992). Hepatocyte transplantation in man. Transplant 
Proc. 24(6):3052-3053 
Mito, M.; Ebata, H.; Kusano, M.; Onishi, T.; Saito, T.; Sakamoto, S. (1979). Morphology and 
function of isolated hepatocytes transplanted into rat spleen. Transplantation 
28(6):499-505 
Moon, YJ.; Yoon, HH.; Lee, MW.; Jang, IK.; Lee, DH.; Lee, JH.; Lee, SK.; Lee, KH.; Kim, YJ.; 
Eom, YW. (2009). Multipotent progenitor cells derived from human umbilical cord 
blood can differentiate into hepatocyte-like cells in a liver injury rat model. 
Transplant Proc. 41(10):4357-4360 
Mori, R.; Sakai, Y. & Nakazawa, K. (2008). Micropatterned organoid culture of rat 
hepatocytes and HepG2 cells. J. Biosci. Bioeng. 106(3):237-242 
Nagata, H.; Ito M.; Shirota, C.; Edge, A.; McCowan, TC.& Fox, IJ. (2003) Route of hepatocyte 
delivery affects hepatocyte engraftment in the spleen. Transplantation.76(4):732-
734 
Oyagi, S.; Hirose, M.; Kojima, M.; Okuyama, M.; Kawase, M.; Nakamura, T.; Ohgushi, H.; 
Yagi, K. (2006). Therapeutic effect of transplanting HGF-treated bone marrow 
mesenchymal cells into CCl4-injured rats. J. Hepatol. 44(4):742-748 
Pei, H.; Yang, Y.; Xi, J.; Bai, Z.; Yue, W.; Nan, X.; Bai, C.; Wang, Y. & Pei, X. (2009). Lineage 
restriction and differentiation of human embryonic stem cells into hepatic 
progenitors and zone 1 hepatocytes. Tissue Eng. Part C Methods 15, 95-104 
Platt, J. (1998). New directions for organ transplantation. Nature. 392:11-17 
Ribeiro, J.; Nordlinger, B.; Ballet, F.; Cynober, L.; Coudray-Lucas, C.; Baudrimont, M.; 
Legendre, C.; Delelo, R. & Panis, Y. (1992). Intrasplenic hepatocellular 
www.intechopen.com
 A Strategy Using Pluripotent Stem Cell-Derived Hepatocytes for Stem Cell-Based Therapies  163 
transplantation corrects hepatic encephalopathy in portacaval-shunted rats. 
Hepatology. 15:12-18 
Rudzok, S.; Schlink, U.; Herbarth, O. & Bauer, M.; (2010). Measuring and modeling of binary 
mixture effects of pharmaceuticals and nickel on cell viability/cytotoxicity in the 
human hepatoma derived cell line HepG2. Toxicol. Pharmacol. 244:336-343 
Sasaki, K.; Miyano, T.; Suruga, K.; Nozawa, R.; Yokota, K. (1983). Isografts of rat hepatocytes 
into intramesenterium. Jap J. Pediatr Surg. 15:1450-1451 
Sasaki, K., Ichikawa, H., Takei, S., No, H., Tomotsune, D., Kano, Y., Yokoyama, T., 
Shirasawa, S., Mogi, A., Yoshie, S., Sasaki, S., Yamada, S., Matsumoto, K., 
Mizuguchi, M., Yue, F. & Tanaka, Y. (2009). Hepatocyte differentiation from human 
ES cells using the simple embryoid body formation method and the staged 
additional cocktail. ScientificWorldJournal 9:884-890 
Schumacher, IK.; Okamoto, T.; Kim, BH.; Chowdhury, NR.; Chowdhury, JR. & Fox, IJ. 
(1996). Transplantation of conditionally immortalized hepatocytes to treat hepatic 
encephalopathy. Hepatology 24:337-343 
Sharma, R.; Greenhough, S.; Medine, CN. & Hay, DC. (2010). Three-dimensional culture of 
human embryonic stem cell derived hepatic endoderm and its role in bioartificial 
liver construction. J. Biomed. Biotechnol. 2010:236147  
Shiraki, N., Umeda, K., Sakashita, N., Takeya M., Kume, K. & Kume, S. (2008). 
Differentiation of mouse and human embryonic stem cells into hepatic lineages. 
Genes Cells 13, 731-746 
Si-Tayeb, K.; Lemaigre, FP. & Duncan, SA.; (2010). Organogenesis and development of the 
liver. Dev Cell. 18(2):175-189  
Soto-Gutierrez A.; Kobayashi N.; Rivas-Carrillo, JD.; Navarro-Alvarez, N.; Zhao, D.; Okitsu, 
T.; Noguchi, H.; Basma, H.; Tabata, Y.; Chen Y.; Tanaka K.; Narushima M.; Miki, 
A.; Ueda, T.; Jun, HS.; Yoon, JW.; Lebkowski, J.; Tanaka, N.; Fox, IJ. (2006). Reversal 
of mouse hepatic failure using an implanted liver-assist device containing ES cell-
derived hepatocytes. Nat. Biotechnol. 24:1412-1419 
Strunk SW. (1959). The formation of intracellular crystals in midgut glands of Limnoria 
lignorum. J. Biophys. Biochem. Cytol. 5(3):385-392 
Sutherland, D. E. R.; Numate M, Matas AJ, Simmons RL, Najaran JS. (1977). Hepatocellular 
transplantation in acute liver failure. Surgery 82:124-132 
Suzuki, A., Zheng, Y.W., Kondo, R., Kusakabe, M., Takada, Y., Fukao, K., Nakauchi, H., and 
Taniguchi, H. (2000). Flow-cytometric separation and enrichment of hepatic 
progenitor cells in the developing mouse liver. Hepatology 32,1230-1239 
Tada, K.; Roy-Chowdhury, N.; Prasad, V.; Kim, BH.; Manchikalapudi, P.; Fox, IJ.; van 
Duijvendijk, P.; Bosma, PJ.; Roy-Chowdhury, J.; (1998). Long-term amelioration of 
bilirubin glucuronidation defect in Gunn rats by transplanting genetically modified 
immortalized autologous hepatocytes. Cell Transplant 7:607-616 
Takashimizu, I.; Tanaka, Y.; Yoshie, S.; Kano, Y.; Ichikawa, H.; Cui, L.; Ogiwara, N.; Johkura. 
K. & Sasaki, K. (2009). Localization of Liv2 in EB Outgrowth. The Scientific World 
Journal 9:190-199  
Takimoto, Y.; Dixit, V.; Arthur, M. & Gitnick G. (2003). De novo liver tissue formation in rats 
using a novel collagen-polypropylene scaffold. Cell Transplant 12(4):413-421 
www.intechopen.com
 Advances in Regenerative Medicine 164 
Teratani, T., Yamamoto H., Aoyagi, K., Sasaki, H., Asari, A., Quinn, G., Sasaki, H., Terada, 
M. & Ochiya, T. (2005). Direct hepatic fate specification from mouse embryonic 
stem cells. Hepatology 41, 836-846 
Torok, E.; Lutgehetmann, M.; Bierwolf, J.; Melbeck, S.; Dullmann, J.; Nashan, B.; Ma, PX. & 
Pollok, JM. (2011). Primary human hepatocytes on biodegradable poly (l-lactic 
acid) matrices: a promising model for improving transplantation efficiency with 
tissue engineering. Liver Transpl. 17(2):104-114 
Watanabe, T.; Nakagawa, K.; Ohata, S.; Kitagawa, D.; Nishitai, G.; Seo, J.; Tanemura, S.; 
Shimizu, N.; Kishimoto, H.; Wada, T.; Aoki, J.; Arai, H.; Iwatsubo, T.; Mochita, M.; 
Watanabe, T.; Satake, M.; Ito, Y.; Matsuyama, T.; Mak, TW.; Penninger, JM.; 
Nishina, H. & Katada, T.炷2002炸 SEK1/MKK4-mediated SAPK/JNK signaling 
participates in embryonic hepatoblast proliferation via a pathway different from 
NF-_B-induced anti-apoptosis. Dev. Biol. 250.; 332-347 
Wong, N.; Lai, P.; Pang, E.; Leung, TW.; Lau, JW. & Johnson, PJ. (2000). A comprehensive 
karyotypic study on human hepatocellular carcinoma by spectral karyotyping. 
Hepatology 32:1060-1068  
Yamada, T.; Yoshikawa, M.; Kanda, S.; Kato, Y.; Nakajima, Y.; Ishizaka, S. & Tsunoda, Y. 
(2002). In vitro differentiation of embryonic stem cells into hepatocyte-like cells 
identified by cellular uptake of indocyanine green. Stem Cells 20(2):146-154  
Yin, Y.; Lim, YK.; Salto-Tellez, Ng SC.; Lin, CS.; Lim, SK. (2002). AFP(+).; ESC-derived cells 
engraft and differentiate into hepatocytes in vivo. Stem Cells ;20:338-346 
Yoshie, S., Shirasawa, S., Yokoyama, T., Kano, Y., Takei, S., Mizuguchi, M., Matsumoto, K., 
Tomotsune, D., and Sasaki, K. (2010). Lanford medium induces high quality 
hepatic lineage cell differentiation directly from mouse embryonic stem cell-
derived mesendoderm. Biochem Biophys Res Commun. 391, 1477-1482 
Yue, F.; Johkura, K.; Shirasawa, S.; Yokoyama, T.; Inoue, Y.; Tomotsune, D. & Sasaki, K. 
(2010). Differentiation of primate ES cells into retinal cells induced by ES cell-
derived pigmented cells. Biochem Biophys Res Commun. 394: 877-883 
Zaret, KS.; (2000). Liver specification and early morphogenesis. Mech. Dev. 92 83-88.  
Zaret, KS.; (2001). Hepatocyte differentiation from the endoderm and beyond. Curr. Opin. 
Genet. Dev.11 568-574 
Zaret, KS. & Grompe, M,; (2008). Generation and regeneration of cells of the liver and 
pancreas. Science 322(5907):1490-1494 
www.intechopen.com
Advances in Regenerative Medicine
Edited by Dr Sabine Wislet-Gendebien
ISBN 978-953-307-732-1
Hard cover, 404 pages
Publisher InTech
Published online 21, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Even if the origins of regenerative medicine can be found in Greek mythology, as attested by the story of
Prometheus, the Greek god whose immortal liver was feasted on day after day by Zeus' eagle; many
challenges persist in order to successfully regenerate lost cells, tissues or organs and rebuild all connections
and functions. In this book, we will cover a few aspects of regenerative medicine highlighting major advances
and remaining challenges in cellular therapy and tissue/organ engineering.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Daihachiro Tomotsune, Fumi Sato, Susumu Yoshie, Sakiko Shirasawa, Tadayuki Yokoyama, Yoshiya Kanoh,
Hinako Ichikawa, Akimi Mogi, Fengming Yue and Katsunori Sasaki (2011). A Strategy Using Pluripotent Stem
Cell-Derived Hepatocytes for Stem Cell-Based Therapies, Advances in Regenerative Medicine, Dr Sabine
Wislet-Gendebien (Ed.), ISBN: 978-953-307-732-1, InTech, Available from:
http://www.intechopen.com/books/advances-in-regenerative-medicine/a-strategy-using-pluripotent-stem-cell-
derived-hepatocytes-for-stem-cell-based-therapies
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
